LCCC 1025: A phase II study evaluating the mTOR inhibitor everolimus with trastuzumab and vinorelbine to treat progressive HER2-positive breast cancer brain metastases. Background: Asignificant amount ...
The hormone therapy tamoxifen can keep cancer from recurring in women with DCIS Tamoxifen following lumpectomy reduced risk of recurrence 44% to 51% Tamoxifen blocks estrogen receptors in cancer cells ...
A polygenic risk score (PRS) may help identify women who are at a greater risk of developing a future breast cancer after treatment for in situ breast disease, a retrospective study suggests. The ...
Adjuvant Trastuzumab Emtansine Versus Paclitaxel in Combination With Trastuzumab for Stage I HER2-Positive Breast Cancer (ATEMPT): A Randomized Clinical Trial Eligibility: Eastern Cooperative Oncology ...
Before breast screening with mammography became routine, ductal carcinoma in situ (DCIS) and high-risk breast lesions were rarely found. Now with the widespread use of mammography, those breast ...
Cancer is typically treated with surgery, radiation and sometimes chemotherapy. But a new study suggests this standard protocol might not be necessary for a common form of early-stage breast cancer.
This is an archived article and the information in the article may be outdated. Please look at the time stamp on the story to see when it was last updated. DURHAM, N.C. (WNCN) — A Duke Researcher’s ...
Overall, the median time from biopsy to treatment was 35 days, but differed significantly between patients whose diagnosis and treatment occurred at the same center (31 days) versus those who sought a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback